News

Aerugen, which was being evaluated for its ability to prevent Pseudomonas aeruginosa infection in cystic fibrosis patients, did not live up to the efficacy results indicated in an

The inclusion of Japan in the deal gives Astellas worldwide rights to this potential treatment for serious infections. Under the extended licensing deal, US-based Theravance will receive an

Non-alcoholic steatohepatitis (NASH) is one stage in a disease spectrum that ranges from simple fatty liver, or steatosis, to steatohepatitis, advanced fibrosis, and end-stage cirrhosis. There is no

The EUA authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved or uncleared medical products or unapproved or uncleared uses

The study will investigate the safety, tolerability, pharmacokinetics and preliminary efficacy of INNO-406 in adult patients with Gleevec-resistant or intolerant Philadelphia positive (Ph+) leukemia or relapsed/refractory Ph+ acute

Gemzar, which is already approved in lung, pancreatic and breast cancer, generated sales of $1.3 billion last year, making it Lilly’s second best-selling drug. In the latest approval,

AFP-464 (aminoflavone pro-drug) is a novel anticancer agent currently being investigated in two phase I clinical trials sponsored by the National Cancer Institute (“NCI”) in patients with solid

The compound is currently being developed in phase I. The two companies plan to jointly develop and commercialize this novel compound for multiple autoimmune disorders. “Together, we are

BL-3020 is a peptide that reduces food intake by binding to specific receptors in the brain that control appetite. In contrast to most peptide-based drugs, it has been